Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Status and phase: Completed; Phase 2

Conditions: Lung Cancer

Treatments: Drug: Placebo; Drug: Sorafenib

Study type: Interventional

Funder types: NETWORK; NIH

Identifiers

NCT00064350

CDR0000315383

E2501 (Other Identifier)

U10CA021115 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is suspended while the drug is administered but returns to baseline rates when the agent is withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized discontinuation design was adopted in the present trial, conducted in a population who were potentially sensitive to sorafenib.

PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works compared to placebo in treating patients with refractory non-small cell lung cancer.

Full description

OBJECTIVES:

To determine the percent of patients maintaining stable disease or objective response two months after randomization with continued sorafenib treatment, compared to patients switched to placebo. To determine progression-free survival, overall survival, and response rate.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to number of prior chemotherapy regimens (2 vs more than 2) and prior epidermal growth factor receptor inhibitor treatment (yes vs no).

Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.

Randomization: Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients who develop disease progression within 1 year after randomization cross over to arm I.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 311 patients will be accrued for this study within approximately 3 years.

Enrollment: 342 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)
• Disease must have progressed after at least 2 prior chemotherapy regimens for NSCLC
• Patients must have measurable or nonmeasurable disease
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 3 times ULN (5 times ULN in patients with liver disease)
• Creatinine less than 1.5 times ULN or calculated creatinine clearance greater than 50 mL/min
• More than 3 weeks since prior chemotherapy, radiotherapy, immunotherapy or other investigational drug use
• Recovered from all prior therapy
• Fertile patients must use effective contraception
• Age >= 18
• ECOG performance status of 0-1

Exclusion criteria

• Prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable and off therapy for at least 2 months

• Active second malignancy

• Clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms of coronary heart disease

• Prior radiotherapy to the only site of measurable or evaluable disease unless there is evidence of disease progression in that site

• Prior exposure to a ras pathway inhibitor (e.g., farnesyl transferase inhibitor)

• Concurrent medications known to be metabolized by the liver with a narrow therapeutic index, including the following:

  • Ketoconazole
  • Itraconazole
  • Quinidine
  • Digoxin
  • Cyclosporine
  • Ritonavir
  • Grapefruit products
  • Carbamazepine
  • Phenytoin
  • Phenobarbital

• Pregnant or nursing

• Clinically serious active infection

• Medical conditions, substance abuse or psychological/social situation that would preclude study participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

342 participants in 3 patient groups, including a placebo group

Induction then Sorafenib

Experimental group

Description:

Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression. Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease.

Treatment:

Drug: Sorafenib

Induction then Placebo then Sorafenib

Placebo Comparator group

Description:

Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression. Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm.

Treatment:

Drug: Sorafenib

Drug: Placebo

Induction, not randomized

Other group

Description:

Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study.

Treatment:

Drug: Sorafenib